Cresco Labs (OTCMKTS:CRLBF) Lowered to Hold Rating by Atb Cap Markets

Cresco Labs (OTCMKTS:CRLBF) was downgraded by equities research analysts at Atb Cap Markets from a “strong-buy” rating to a “hold” rating in a report released on Monday,Zacks.com reports.

Several other equities analysts have also recently weighed in on the stock. Cormark cut shares of Cresco Labs from a “moderate buy” rating to a “hold” rating in a research note on Monday, November 11th. Roth Capital raised shares of Cresco Labs to a “strong-buy” rating in a research report on Sunday, November 10th. Finally, Needham & Company LLC reaffirmed a “hold” rating on shares of Cresco Labs in a report on Monday, August 12th. Four equities research analysts have rated the stock with a hold rating, two have assigned a buy rating and two have issued a strong buy rating to the stock. Based on data from MarketBeat.com, Cresco Labs has an average rating of “Moderate Buy” and an average target price of $2.50.

Cresco Labs Stock Down 0.0 %

CRLBF stock opened at $1.08 on Monday. The company has a market cap of $524.75 million, a price-to-earnings ratio of -5.38 and a beta of 1.73. Cresco Labs has a twelve month low of $1.02 and a twelve month high of $2.65. The business has a 50 day moving average price of $1.40 and a two-hundred day moving average price of $1.58. The company has a quick ratio of 1.39, a current ratio of 1.97 and a debt-to-equity ratio of 1.80.

About Cresco Labs

Cresco Labs Inc, together with its subsidiaries, cultivates, manufactures, and sells retail and medical cannabis products in the United States. It provides cannabis in flowers, vape pens, live resins, disposable pens, and extracts under the Cresco brand; vape carts, vape pens, flower, popcorn, shake, pre-rolls, shorties, and concentrates under the High Supply brand; vapes and gummies under the Good News brand; vapes and edibles under the Wonder Wellness Co brand; and tinctures, capsules, salves, and sublingual oils under the Remedi brand.